Biosergen
49.00 SEK
+8.88 %
Less than 1K followers
BIOSGN
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+8.88 %
+4.02 %
+4.02 %
-22.96 %
-7.56 %
-32.14 %
-33.71 %
-
-86.75 %
Biosergen is active in biotechnology. The company specializes in the research and development of antifungal drugs. The product portfolio includes, for example, an antifungal drug for the treatment of invasive fungal infections in immunosuppressed patients. The company collaborates with research institutes and pharmaceutical companies internationally. Biosergen was founded in 2004 and is headquartered in Solna.
Read moreMarket cap
115.05M SEK
Turnover
91.63K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
10/2
2026
Annual report '25
6/5
2026
Interim report Q1'26
19/5
2026
General meeting '26
All
Press releases
3rd party
ShowingAll content types
Biosergen AB: Determination of Record Date for Reverse Share Split in Biosergen
BioStock: Biosergen kommenterar fortsatta framsteg under tredje kvartalet
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools